Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (vol 374, pg 796, 2009)

被引：0
|
作者：
Lennox, J. L.
Dejesus, E.
Lazzarin, A.
机构：
来源：
LANCET | 2009年 / 374卷 / 9692期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [41] Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID) : 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial (vol 4, e284, 2017)
    Aberg, J. A.
    Sponseller, C. A.
    Ward, D. J.
    LANCET HIV, 2017, 4 (07): : E283 - E283
  • [42] Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
    Calmy, Alexandra
    Sanchez, Tamara Tovar
    Kouanfack, Charles
    Mpoudi-Etame, Mireille
    Leroy, Sandrine
    Perrineau, Segolene
    Wandji, Martial Lantche
    Tata, Darius Tetsa
    Bassega, Pierette Omgba
    Bwenda, Therese Abong
    Varloteaux, Marie
    Tongo, Marcel
    Mpoudi-Ngole, Eitel
    Montoyo, Alice
    Mercier, Noemie
    LeMoing, Vincent
    Peeters, Martine
    Reynes, Jacques
    LANCET HIV, 2020, 7 (10): : E677 - E687
  • [43] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (vol 2, pg 369, 2014)
    Barnett, A. H.
    Mithal, A.
    Manassie, J.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (03): : E2 - E2
  • [44] Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Wohl, David A.
    Yazdanpanah, Yazdan
    Baumgarten, Axel
    Clarke, Amanda
    Thompson, Melanie A.
    Brinson, Cynthia
    Hagins, Debbie
    Ramgopal, Moti N.
    Antinori, Andrea
    Wei, Xuelian
    Acosta, Rima
    Collins, Sean E.
    Brainard, Diana
    Martin, Hal
    LANCET HIV, 2019, 6 (06): : E355 - E363
  • [45] Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine versus 3-drug antiretroviral regimens in treatment-naive HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis
    Nickel, K.
    Halfpenny, N.
    Snedecor, S.
    Punekar, Y.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 109 - 110
  • [46] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Jacobson, Ira M.
    Dore, Gregory J.
    Foster, Graham R.
    Fried, Michael W.
    Radu, Monica
    Rafalsky, Vladimir V.
    Moroz, Larysa
    Craxi, Antonio
    Peeters, Monika
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    De La Rosa, Guy
    Kalmeijer, Ronald
    Scott, Jane
    Sinha, Rekha
    Beumont-Mauviel, Maria
    LANCET, 2014, 384 (9941): : 403 - 413
  • [47] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
    Sax, Paul E.
    DeJesus, Edwin
    Mills, Anthony
    Zolopa, Andrew
    Cohen, Calvin
    Wohl, David
    Gallant, Joel E.
    Liu, Hui C.
    Zhong, Lijie
    Yale, Kitty
    White, Kirsten
    Kearney, Brian P.
    Szwarcberg, Javier
    Quirk, Erin
    Cheng, Andrew K.
    LANCET, 2012, 379 (9835): : 2439 - 2448
  • [48] Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial
    Saxena, Deepti
    Spino, Michael
    Tricta, Fernando
    Connelly, John
    Cracchiolo, Bernadette M.
    Hanauske, Axel-Rainer
    Gandolfi, Darlene D'Alliessi
    Mathews, Michael B.
    Karn, Jonathan
    Holland, Bart
    Park, Myung Hee
    Pe'ery, Tsafi
    Palumbo, Paul E.
    Hanauske-Abel, Hartmut M.
    PLOS ONE, 2016, 11 (05):
  • [49] Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial (vol 16, pg 43, 2017)
    Baulac, M.
    Rosenow, F.
    Toledo, M.
    LANCET NEUROLOGY, 2017, 16 (02): : 102 - 102
  • [50] Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial (vol 21, pg 823, 2021)
    Hsu, Y-C
    Chen, C-Y
    Chang, I-W
    LANCET INFECTIOUS DISEASES, 2021, 21 (05): : E122 - E122
12345